This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: January 6, 2005
Last updated: October 12, 2016
Last verified: October 2016

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with metastatic or inoperable thyroid cancer.

Condition Intervention Phase
Head and Neck Cancer Drug: irinotecan hydrochloride Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer

Resource links provided by NLM:

Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • Response rate [ Time Frame: Every 2 cycles ]
    To determine the response rate of this regimen of irinotecan in patients with metastatic MTC

Enrollment: 6
Study Start Date: November 2004
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Irinotecan Drug: irinotecan hydrochloride

Detailed Description:



  • Determine the response rate in patients with metastatic or inoperable locoregional medullary thyroid cancer treated with irinotecan.


  • Determine the safety and tolerability of this drug in these patients.

OUTLINE: Patients receive irinotecan IV on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Response is assessed after completion of 4 courses. Patients achieving complete response (CR) or partial response (PR) receive 2 additional courses beyond CR or PR. Patients who have stable disease receive up to 12 total courses.

PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed medullary thyroid cancer

    • Metastatic or inoperable locoregional disease
  • Measurable disease by CT scan

    • Patients with elevated calcitonin levels as the only measurement of disease are not eligible



  • 18 and over

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • Granulocyte count > 1,000/mm^3
  • Platelet count > 100,000/mm^3


  • Bilirubin < 1.5 mg/dL
  • ALT and AST < 2.5 times upper limit of normal
  • No unstable or uncompensated hepatic disease


  • Creatinine clearance > 60 mL/min
  • No unstable or uncompensated renal disease


  • No unstable or uncompensated cardiovascular disease


  • No unstable or uncompensated respiratory disease


  • Not pregnant or nursing
  • Negative pregnancy test
  • No diarrhea ≥ grade 2 (antidiarrheals allowed)
  • No other severe or uncontrolled systemic disease
  • No other malignancy within the past 5 years except squamous cell or basal cell skin cancer or cervical cancer
  • No other illness that would preclude study participation
  • No other significant clinical disorder or laboratory finding that would preclude study participation


Biologic therapy

  • More than 3 months since prior biologic therapy


  • More than 3 months since prior chemotherapy

Endocrine therapy

  • Not specified


  • No prior radiotherapy to > 25% of bone marrow
  • More than 3 months since prior radiotherapy


  • Recovered from prior oncologic or other major surgery


  • More than 30 days since prior non-approved or investigational drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00100828

United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410
United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109-0942
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Arlene A. Forastiere, MD Sidney Kimmel Comprehensive Cancer Center
  More Information

Responsible Party: Sidney Kimmel Comprehensive Cancer Center Identifier: NCT00100828     History of Changes
Other Study ID Numbers: JHOC-J0459, CDR0000409567
P50CA096784 ( U.S. NIH Grant/Contract )
P30CA006973 ( U.S. NIH Grant/Contract )
Study First Received: January 6, 2005
Last Updated: October 12, 2016

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
thyroid gland medullary carcinoma
recurrent thyroid cancer

Additional relevant MeSH terms:
Head and Neck Neoplasms
Thyroid Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Endocrine System Diseases
Thyroid Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017